company background image
VYGR

Voyager Therapeutics NasdaqGS:VYGR Stock Report

Last Price

US$5.76

Market Cap

US$221.5m

7D

15.2%

1Y

32.4%

Updated

26 Jun, 2022

Data

Company Financials +
VYGR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

VYGR Stock Overview

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies.

Voyager Therapeutics Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Voyager Therapeutics
Historical stock prices
Current Share PriceUS$5.76
52 Week HighUS$10.60
52 Week LowUS$2.46
Beta1.1
1 Month Change0.17%
3 Month Change-38.98%
1 Year Change32.41%
3 Year Change-78.84%
5 Year Change-35.71%
Change since IPO-67.55%

Recent News & Updates

Jun 08

Looking Back In On Voyager Therapeutics

Today, we revisit Voyager Therapeutics for the first time in a year. The company has signed licensing deals with two large drug makers since we last looked in on it and net cash represents most of the stock's current market capitalization. A full investment analysis follows in the paragraphs below.

May 12
Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

The analysts covering Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) delivered a dose of negativity to shareholders today...

Shareholder Returns

VYGRUS BiotechsUS Market
7D15.2%10.3%6.6%
1Y32.4%-24.3%-18.4%

Return vs Industry: VYGR exceeded the US Biotechs industry which returned -24.4% over the past year.

Return vs Market: VYGR exceeded the US Market which returned -18.5% over the past year.

Price Volatility

Is VYGR's price volatile compared to industry and market?
VYGR volatility
VYGR Average Weekly Movement16.8%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: VYGR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: VYGR's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2013101Al Sandrockhttps://www.voyagertherapeutics.com

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company’s lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson’s disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington’s disease; VY-FXN01 for Friedreich’s ataxia; and Tau program for the treatment of tauopathies, including Alzheimer’s disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.

Voyager Therapeutics Fundamentals Summary

How do Voyager Therapeutics's earnings and revenue compare to its market cap?
VYGR fundamental statistics
Market CapUS$221.51m
Earnings (TTM)-US$70.87m
Revenue (TTM)US$31.57m

7.0x

P/S Ratio

-3.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VYGR income statement (TTM)
RevenueUS$31.57m
Cost of RevenueUS$65.79m
Gross Profit-US$34.22m
Other ExpensesUS$36.65m
Earnings-US$70.87m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.84
Gross Margin-108.38%
Net Profit Margin-224.46%
Debt/Equity Ratio0%

How did VYGR perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is VYGR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VYGR?

Other financial metrics that can be useful for relative valuation.

VYGR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.1x
Enterprise Value/EBITDA-1.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does VYGR's PS Ratio compare to its peers?

VYGR PS Ratio vs Peers
The above table shows the PS ratio for VYGR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1212.2x

Price-To-Sales vs Peers: VYGR is good value based on its Price-To-Sales Ratio (7x) compared to the peer average (1212.2x).


Price to Earnings Ratio vs Industry

How does VYGR's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Sales vs Industry: VYGR is good value based on its Price-To-Sales Ratio (7x) compared to the US Biotechs industry average (14.1x)


Price to Sales Ratio vs Fair Ratio

What is VYGR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VYGR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7x
Fair PS Ratio0.7x

Price-To-Sales vs Fair Ratio: VYGR is expensive based on its Price-To-Sales Ratio (7x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).


Share Price vs Fair Value

What is the Fair Price of VYGR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VYGR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VYGR's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VYGR's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Voyager Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-10.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VYGR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VYGR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VYGR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VYGR's revenue is expected to decline over the next 3 years (-8.8% per year).

High Growth Revenue: VYGR's revenue is forecast to decline over the next 3 years (-8.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VYGR is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Voyager Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


17.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: VYGR is currently unprofitable.

Growing Profit Margin: VYGR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VYGR is unprofitable, but has reduced losses over the past 5 years at a rate of 17.6% per year.

Accelerating Growth: Unable to compare VYGR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VYGR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: VYGR has a negative Return on Equity (-93.33%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Voyager Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: VYGR's short term assets ($170.7M) exceed its short term liabilities ($101.7M).

Long Term Liabilities: VYGR's short term assets ($170.7M) exceed its long term liabilities ($46.6M).


Debt to Equity History and Analysis

Debt Level: VYGR is debt free.

Reducing Debt: VYGR has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable VYGR has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: VYGR is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 11.1% per year.


Discover healthy companies

Dividend

What is Voyager Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate VYGR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VYGR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VYGR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VYGR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VYGR has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Al Sandrock (63 yo)

0.25

Tenure

Dr. Alfred W. Sandrock Jr., also known as Al, M.D., Ph D., served as Director at Verge Analytics, Inc. since February 2022. He serves as Member of Scientific Advisory Board at Camp4 Therapeutics Corporatio...


Leadership Team

Experienced Management: VYGR's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: VYGR's board of directors are considered experienced (5.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Voyager Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Voyager Therapeutics, Inc.
  • Ticker: VYGR
  • Exchange: NasdaqGS
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$221.507m
  • Shares outstanding: 38.46m
  • Website: https://www.voyagertherapeutics.com

Number of Employees


Location

  • Voyager Therapeutics, Inc.
  • 75 Sidney Street
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.